MedTrace Logo

A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients

NCT01228058 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1450

Last updated 2012-12-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical utility of thrombelastography (TEG) to predict and identify trauma patients at increased risk of receiving blood transfusion, develop multiple organ failure and mortality.

TEG has been proposed as a superior tool to rapidly diagnose and help guide resuscitation with blood products and preclinical data suggest that TEG is both more sensitive and specific than PT or PTT for coagulation abnormalities. Based on the preclinical work led by Dr. Holcomb, our hypothesis is that the Rapid TEG will help to identify these coagulopathic patients earlier, allow for rapid MT protocol activation, and assist in developing data driven blood product transfusion guidelines.

Conditions

  • Coagulopathy

Interventions

PROCEDURE

RapidTEG test

The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).

Sponsors & Collaborators

  • Haemonetics Corporation

    collaborator INDUSTRY

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Bryan Cotton, MD · The University of Texas Health Science Center, Houston

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01228058 on ClinicalTrials.gov